At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
LNP023drug
Likely dose
LNP023 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Non-randomized Study on Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LNP023 in Two Patient Populations With C3 Glomerulopathy
In Brief
A Phase 2 clinical trial evaluating LNP023 for Glomerulonephritis. Completed, enrolled 27 participants across 9 sites in 6 countries.
Detailed Summary
The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlomerulonephritis
CountriesFrance, Germany, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartFeb 2019
Primary CompletionApr 2021
TodayJul 2026
First PostedFeb 6, 2019
Enrollment StartFeb 20, 2019
Primary CompletionApr 23, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.4 years ago
Interventions
LNP023drug
Increasing doses of LNP023 up to 200 mg.